Key findings of the 2026 Patient Recruitment Roundup:
Overall MER fell to a four-year low, Phase IV trials lead enrollment, enrollment duration has risen sharply, Asia outperforms across the board, vaccines are the fastest-enrolling trials, and non-industry trials surpass industry-sponsored trials.